Your session is about to expire
← Back to Search
CAR T Cell Therapy for Glioblastoma (IMPACT Trial)
IMPACT Trial Summary
This trial is to see if it's safe to use IL-8 receptor modified patient-derived activated CD70 CAR T cells to treat brain cancer.
IMPACT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.IMPACT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been cancer-free for over 3 years, except for non-melanoma skin cancer.I do not have HIV or any diseases that weaken my immune system.My tumor is located in the upper part of my brain.I have been newly diagnosed with a high-grade brain tumor without any previous brain tumor history.I am able to care for myself but may not be able to do active work.My cancer has spread to the lining of my brain and spine, but it's limited.My liver tests are within the required limits.I am 18 years old or older.I am not eligible for cellular therapy as determined by a transplant specialist.I am willing to use birth control during and for 6 months after the study.My cancer has spread to the lower part of my brain or outside of it.My brain tumor has come back or is found in multiple places.My kidney function is good, with normal BUN and creatinine levels.My cancer tests positive for CD70.I agree to use birth control during the study and for 24 weeks after the last dose.My tumor was surgically removed and is smaller than 3cm x 3cm on MRI.
- Group 1: 8R-70CAR T cells
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any unfilled vacancies for participants in this research?
"The details hosted on clinicaltrials.gov indicate that this trial has concluded its search for participants, with the last update occuring on July 29th 2021. Yet, there still remains 442 other medical studies actively accepting patients at present time."
Is it possible to join this clinical research endeavor?
"This medical trial is currently enrolling 18 persons with glioblastoma ranging from 18 to 80 years of age. For eligibility, patients must fulfil the following criteria: Age ≥18; Supratentorial growth pattern; MGMT-unmethylated & CD70 positive (≥20%, 1+); Low/Moderate/High level expression; Negative score for 0 staining intensity; No prior brain tumours as per WHO Grade IV glioma histopathology or molecular assessment (secondary GBM not accepted); At least 20% of cells scoring 1+ staining intensity (>20%, 1+).."
Is the age threshold for participation in this study restricted to below 20 years old?
"Eligibility for this clinical trial requires patients to be between 18 and 80 years old. Separately, there are 35 trials that offer treatments exclusively to those below the age of consent as well as 416 studies targeting elderly individuals over 65."
What risk factors should be taken into account when considering Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cell treatments?
"Clinical data on the safety and efficacy of Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells is limited, so our team at Power assigned it a score of 1."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger